LMCD1

Summary

LMCD1 (LIM and cysteine rich domains 1, HGNC:6633) is a protein-coding gene on chromosome 3p25.3, encoding LIM and cysteine-rich domains protein 1 (Q9NZU5). Transcriptional cofactor that restricts GATA6 function by inhibiting DNA-binding, resulting in repression of GATA6 transcriptional activation of downstream target genes.

This gene encodes a member of the LIM-domain family of zinc finger proteins. The encoded protein contains an N-terminal cysteine-rich domain and two C-terminal LIM domains. The presence of LIM domains suggests involvement in protein-protein interactions. The protein may act as a co-regulator of transcription along with other transcription factors. Alternate splicing results in multiple transcript variants of this gene.

Source: NCBI Gene 29995 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 87 total — 1 pathogenic
• MANE Select transcript: NM_014583

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6633
Approved symbol	LMCD1
Name	LIM and cysteine rich domains 1
Location	3p25.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000071282
Ensembl biotype	protein_coding
OMIM	604859
Entrez	29995

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 10 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000157600, ENST00000397386, ENST00000415597, ENST00000426878, ENST00000454244, ENST00000456506, ENST00000470776, ENST00000880274, ENST00000921338, ENST00000957327, ENST00000957328, ENST00000957329

RefSeq mRNA: 4 — MANE Select: NM_014583 NM_001278233, NM_001278234, NM_001278235, NM_014583

CCDS: CCDS33688, CCDS63532, CCDS63533, CCDS63534

Canonical transcript exons

ENST00000157600 — 6 exons

Exon	Start	End
ENSE00001651667	8567440	8574668
ENSE00001864301	8501823	8501980
ENSE00003470072	8537185	8537440
ENSE00003473509	8565432	8565647
ENSE00003643898	8548568	8548903
ENSE00003735520	8532737	8532825

Expression profiles

Bgee: expression breadth ubiquitous, 257 present calls, max score 99.21.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 33.7936 / max 1017.8956, expressed in 1452 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
35186	24.2897	1313
35187	6.0778	1286
35188	1.9310	953
35189	0.8814	568
35190	0.5799	329
35185	0.0339	8

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
hindlimb stylopod muscle	UBERON:0004252	99.21	gold quality
ascending aorta	UBERON:0001496	99.19	gold quality
thoracic aorta	UBERON:0001515	99.18	gold quality
descending thoracic aorta	UBERON:0002345	99.14	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.93	gold quality
right lung	UBERON:0002167	98.75	gold quality
biceps brachii	UBERON:0001507	98.50	gold quality
aorta	UBERON:0000947	98.48	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.42	gold quality
popliteal artery	UBERON:0002250	98.01	gold quality
tibial artery	UBERON:0007610	98.00	gold quality
body of tongue	UBERON:0011876	97.88	gold quality
gastrocnemius	UBERON:0001388	97.73	gold quality
muscle of leg	UBERON:0001383	97.65	gold quality
vena cava	UBERON:0004087	97.58	gold quality
triceps brachii	UBERON:0001509	97.49	gold quality
omental fat pad	UBERON:0010414	97.34	gold quality
peritoneum	UBERON:0002358	97.31	gold quality
upper lobe of left lung	UBERON:0008952	97.31	gold quality
gluteal muscle	UBERON:0002000	97.09	gold quality
saphenous vein	UBERON:0007318	97.05	gold quality
right coronary artery	UBERON:0001625	97.03	gold quality
left coronary artery	UBERON:0001626	97.00	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.95	gold quality
upper lobe of lung	UBERON:0008948	96.89	gold quality
gall bladder	UBERON:0002110	96.82	gold quality
coronary artery	UBERON:0001621	96.73	gold quality
left uterine tube	UBERON:0001303	96.55	gold quality
muscle organ	UBERON:0001630	96.41	gold quality
skeletal muscle organ	UBERON:0014892	96.41	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-ENAD-27	yes	313.24
E-MTAB-10287	yes	67.51
E-MTAB-6701	yes	27.17
E-HCAD-11	yes	7.72
E-GEOD-130148	yes	4.29
E-ENAD-17	no	171.06
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA6

miRNA regulators (miRDB)

35 targeting LMCD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4713-3P	100.00	65.92	505
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-2392	99.43	67.50	708
HSA-MIR-6505-3P	99.34	67.39	1071
HSA-MIR-7974	99.24	65.48	1137
HSA-MIR-196A-3P	99.19	67.34	1204
HSA-MIR-4711-3P	98.97	66.87	1020
HSA-MIR-511-5P	98.97	70.94	2268
HSA-MIR-6830-3P	98.62	68.07	1760
HSA-MIR-1178-3P	98.57	67.09	890
HSA-MIR-599	98.32	66.99	1037
HSA-MIR-6509-3P	98.32	67.33	1343
HSA-MIR-1304-3P	98.29	66.44	1207
HSA-MIR-2681-3P	98.18	65.28	577
HSA-MIR-1285-5P	98.01	68.71	779
HSA-MIR-4646-5P	97.70	66.84	1692
HSA-MIR-4715-5P	97.62	67.47	506
HSA-MIR-450B-3P	97.56	66.12	512
HSA-MIR-96-3P	97.47	68.03	839
HSA-MIR-4436B-5P	96.71	68.37	1346

Literature-anchored findings (GeneRIF, showing 9)

• Together, our results suggest that LMCD1 mutations are potential oncogenic events in HCC metastasis to promote cell migration through the Rac1-signaling pathway. (PMID:21996735)
• The rs1800775 [1.31 (1.22-1.42); p = 3.41E-12] in the CETP gene and rs359027 [1.26 (1.16-1.36); p = 2.55E-08] in the LMCD1 gene were significantly associated with LHDLC levels (PMID:26879886)
• LIM and cysteine-rich domains 1 is required for thrombin-induced smooth muscle cell proliferation and promotes atherogenesis (PMID:29326163)
• LMCD1 promotes osteogenic differentiation of human bone marrow stem cells by regulating BMP signaling. (PMID:31501411)
• Skeletal muscle LMCD1 expression is reduced in patients with skeletal muscle disease. We analyzed gene expression data from muscle of patients with diverse muscle pathologies and identified LMCD1 as a gene strongly associated with skeletal muscle function. (PMID:31666122)
• LMCD1 acts as an activator of E2F1 in humans in the induction of CDC6 and IL-33 expression during development of vascular lesions. (PMID:32160773)
• LMCD1 facilitates the induction of pluripotency via cell proliferation, metabolism, and epithelial-mesenchymal transition. (PMID:35842772)
• Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung Fibrosis. (PMID:36103378)
• LIM and Cysteine-Rich Domains 1 Promotes Transforming Growth Factor beta1-Induced Epithelial-Mesenchymal Transition in Human Kidney 2 Cells. (PMID:37039151)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	lmcd1	ENSDARG00000002002
mus_musculus	Lmcd1	ENSMUSG00000057604
rattus_norvegicus	Lmcd1	ENSRNOG00000005690
drosophila_melanogaster	Tes	FBGN0034223
caenorhabditis_elegans		WBGENE00004112
caenorhabditis_elegans		WBGENE00015217

Paralogs (3): TES (ENSG00000135269), LIMD2 (ENSG00000136490), PRICKLE1 (ENSG00000139174)

Protein

Protein identifiers

LIM and cysteine-rich domains protein 1 — Q9NZU5 (reviewed: Q9NZU5)

Alternative names: Dyxin

All UniProt accessions (5): Q9NZU5, B4DEY6, C9IYS1, F8WB09, H7C3D2

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional cofactor that restricts GATA6 function by inhibiting DNA-binding, resulting in repression of GATA6 transcriptional activation of downstream target genes. Represses GATA6-mediated trans activation of lung- and cardiac tissue-specific promoters. Inhibits DNA-binding by GATA4 and GATA1 to the cTNC promoter. Plays a critical role in the development of cardiac hypertrophy via activation of calcineurin/nuclear factor of activated T-cells signaling pathway.

Subunit / interactions. Interacts with GATA1 and GATA4. Interacts with beta-dystroglycan. Interacts with GATA6.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed in the heart (at protein level). Expressed in many tissues with highest abundance in skeletal muscle.

Domain organisation. The LIM zinc-binding domains and the Cys-rich region mediate interaction with GATA6.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NZU5-1	1	yes
Q9NZU5-2	2

RefSeq proteins (4): NP_001265162, NP_001265163, NP_001265164, NP_055398* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001781	Znf_LIM	Domain
IPR010442	PET_domain	Domain
IPR033724	PET_testin	Domain
IPR047120	Pk/Esn/Tes	Family

Pfam: PF00412, PF06297

UniProt features (8 total): domain 3, chain 1, region of interest 1, compositionally biased region 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NZU5-F1	85.63	0.66

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 16

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-5683826	Surfactant metabolism
R-HSA-392499	Metabolism of proteins

MSigDB gene sets: 179 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, ATF_B, GOBP_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, GOZGIT_ESR1_TARGETS_DN, GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP, CREB_Q4, GOBP_POSITIVE_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, SRF_C, ATF1_Q6, GOBP_MUSCLE_ADAPTATION, ENGELMANN_CANCER_PROGENITORS_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, AAAGACA_MIR511

GO Biological Process (3): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of cardiac muscle hypertrophy (GO:0010611), positive regulation of calcineurin-NFAT signaling cascade (GO:0070886)

GO Molecular Function (4): transcription corepressor activity (GO:0003714), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
negative regulation of DNA-templated transcription	2
cellular anatomical structure	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
cardiac muscle hypertrophy	1
regulation of muscle hypertrophy	1
regulation of muscle adaptation	1
calcineurin-NFAT signaling cascade	1
regulation of calcineurin-NFAT signaling cascade	1
positive regulation of calcineurin-mediated signaling	1
transcription coregulator activity	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

986 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LMCD1	DLX2	Q07687	687
LMCD1	GATA6	P78327	623
LMCD1	EIF1B	O60739	571
LMCD1	VSTM2B	A6NLU5	447
LMCD1	TNS1	Q9HBL0	446
LMCD1	MRPS21	P82921	434
LMCD1	RAB31	Q13636	413
LMCD1	DCHS1	Q96JQ0	407
LMCD1	TAF6L	Q9Y6J9	405
LMCD1	WNT3A	P56704	401
LMCD1	SSUH2	Q9Y2M2	379
LMCD1	ROBO1	Q9Y6N7	375
LMCD1	ECM1	Q16610	372
LMCD1	HTR2B	P41595	371
LMCD1	LTA4H	P09960	359

IntAct

40 interactions, top by confidence:

A	B	Type	Score
CNOT3	CNOT1	psi-mi:“MI:0914”(association)	0.740
RABIF	LMCD1	psi-mi:“MI:0915”(physical association)	0.560
TEKT4	LMCD1	psi-mi:“MI:0915”(physical association)	0.560
GPS1	PXDNL	psi-mi:“MI:0914”(association)	0.530
MCRIP2	CASC3	psi-mi:“MI:0914”(association)	0.530
TPD52L1	TPD52L2	psi-mi:“MI:0914”(association)	0.530
LMCD1	DUX4	psi-mi:“MI:0915”(physical association)	0.400
LMCD1	TCERG1	psi-mi:“MI:0915”(physical association)	0.400
LMCD1	tyeA	psi-mi:“MI:0915”(physical association)	0.370
TRIM63	LMCD1	psi-mi:“MI:0915”(physical association)	0.370
LMCD1	SMURF2	psi-mi:“MI:0915”(physical association)	0.370
	SHTN1	psi-mi:“MI:0914”(association)	0.350
AZU1	UBA6	psi-mi:“MI:0914”(association)	0.350
BCAS2	ISY1-RAB43	psi-mi:“MI:0914”(association)	0.350
DCTN3	PSMG1	psi-mi:“MI:0914”(association)	0.350
DDX28	UBA6	psi-mi:“MI:0914”(association)	0.350
DND1	UBA6	psi-mi:“MI:0914”(association)	0.350
GAB2	UBA6	psi-mi:“MI:0914”(association)	0.350
IL2RG	BBOX1	psi-mi:“MI:0914”(association)	0.350
KIAA1191	UBA6	psi-mi:“MI:0914”(association)	0.350
LGALS9	CYB5A	psi-mi:“MI:0914”(association)	0.350
LPXN	MED14	psi-mi:“MI:0914”(association)	0.350
MARS2	DDX39A	psi-mi:“MI:0914”(association)	0.350
MRPL49	UBA6	psi-mi:“MI:0914”(association)	0.350
MRPS23	MYH7B	psi-mi:“MI:0914”(association)	0.350
NMNAT2	TOMM40	psi-mi:“MI:0914”(association)	0.350
NPPB	ACOT7	psi-mi:“MI:0914”(association)	0.350
OSBPL11	DNM1L	psi-mi:“MI:0914”(association)	0.350
PEX7	UBA6	psi-mi:“MI:0914”(association)	0.350
PPP4R2	KRIT1	psi-mi:“MI:0914”(association)	0.350

BioGRID (29): LMCD1 (Two-hybrid), LMCD1 (Two-hybrid), LMCD1 (Proximity Label-MS), TEKT4 (Two-hybrid), RABIF (Two-hybrid), LMCD1 (Affinity Capture-MS), LMCD1 (Affinity Capture-MS), LMCD1 (Proximity Label-MS), LMCD1 (Affinity Capture-Western), LMCD1 (Affinity Capture-MS), NIPSNAP3A (Co-fractionation), GGA2 (Co-fractionation), PCTP (Co-fractionation), LMCD1 (Affinity Capture-MS), LMCD1 (Positive Genetic)

ESM2 similar proteins: A0JMY5, A2YEZ6, A3BDI8, A6QLA0, A9YUB1, B1AY10, D4A4T9, E0X9N4, O74853, P40798, P47226, P53971, Q09YN8, Q0D5B9, Q108U9, Q12986, Q15326, Q17QE2, Q18034, Q29RL2, Q2IBC3, Q2LAP6, Q2QLA1, Q2QLG8, Q4R7U2, Q54BK0, Q5PXT2, Q5R966, Q5RD91, Q5U2P3, Q5ZA07, Q5ZML4, Q67YE6, Q6DIR5, Q6IDS6, Q6NUA0, Q6ZNB6, Q7ZXE9, Q8N6M9, Q8R5C8

Diamond homologs: A0A1L8F1M4, A0M8R4, A0M8S5, A0M8U6, A1Z6W3, A8WH69, O43294, O43900, P47226, Q00PK1, Q04650, Q07DW1, Q07DX3, Q07DY3, Q07DZ4, Q07E27, Q07E40, Q07E51, Q09YI0, Q09YJ2, Q09YK3, Q09YL5, Q09YN8, Q108U9, Q174I2, Q17QE2, Q28FG2, Q292U2, Q292U5, Q2IBA3, Q2IBC3, Q2IBH0, Q2LAP6, Q2QL92, Q2QLA1, Q2QLB2, Q2QLC3, Q2QLE3, Q2QLF4, Q2QLG8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	66
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1526995	GRCh37/hg19 3p26.1-25.3(chr3:6842555-10153209)	Pathogenic

SpliceAI

1069 predictions. Top by Δscore:

Variant	Effect	Δscore
3:8501978:AAGG:A	donor_loss	1.0000
3:8501979:AGGTG:A	donor_loss	1.0000
3:8501980:GGT:G	donor_loss	1.0000
3:8501981:GTGA:G	donor_loss	1.0000
3:8548563:CCTA:C	acceptor_loss	1.0000
3:8548564:CTAG:C	acceptor_loss	1.0000
3:8548565:TAG:T	acceptor_loss	1.0000
3:8548566:A:AG	acceptor_gain	1.0000
3:8548566:A:G	acceptor_loss	1.0000
3:8548566:AG:A	acceptor_gain	1.0000
3:8548567:G:GG	acceptor_gain	1.0000
3:8548567:GG:G	acceptor_gain	1.0000
3:8548898:GAA:G	donor_gain	1.0000
3:8548900:ATAC:A	donor_gain	1.0000
3:8548900:ATACG:A	donor_loss	1.0000
3:8548901:TAC:T	donor_gain	1.0000
3:8548901:TACG:T	donor_loss	1.0000
3:8548902:ACGT:A	donor_loss	1.0000
3:8548903:CGTA:C	donor_loss	1.0000
3:8548904:G:C	donor_loss	1.0000
3:8548904:G:GG	donor_gain	1.0000
3:8548905:T:TG	donor_loss	1.0000
3:8548906:A:AT	donor_loss	1.0000
3:8501978:AAG:A	donor_gain	0.9900
3:8501981:G:GG	donor_gain	0.9900
3:8501982:T:A	donor_loss	0.9900
3:8537440:GGTAA:G	donor_loss	0.9900
3:8537441:G:C	donor_loss	0.9900
3:8537442:T:TC	donor_loss	0.9900
3:8548566:AGG:A	acceptor_gain	0.9900

AlphaMissense

2383 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:8537390:T:C	F113L	1.000
3:8537392:T:A	F113L	1.000
3:8537392:T:G	F113L	1.000
3:8537411:T:A	W120R	1.000
3:8537411:T:C	W120R	1.000
3:8537413:G:C	W120C	1.000
3:8537413:G:T	W120C	1.000
3:8537192:T:C	C47R	0.999
3:8537262:G:A	G70D	0.999
3:8537336:A:G	K95E	0.999
3:8537338:G:C	K95N	0.999
3:8537338:G:T	K95N	0.999
3:8537340:G:T	R96M	0.999
3:8537341:G:C	R96S	0.999
3:8537341:G:T	R96S	0.999
3:8537391:T:C	F113S	0.999
3:8537405:T:G	Y118D	0.999
3:8548577:T:G	Y133D	0.999
3:8548662:T:C	L161P	0.999
3:8548770:G:A	G197E	0.999
3:8565478:T:A	V257D	0.999
3:8565531:T:C	C275R	0.999
3:8565562:T:C	L285P	0.999
3:8565594:T:C	C296R	0.999
3:8565630:T:C	C308R	0.999
3:8565632:C:G	C308W	0.999
3:8537193:G:A	C47Y	0.998
3:8537194:C:G	C47W	0.998
3:8537202:G:A	C50Y	0.998
3:8537249:G:C	D66H	0.998

dbSNP variants (sampled 300 via entrez): RS1000013945 (3:8558496 G>A), RS1000024491 (3:8517515 G>A,T), RS1000044408 (3:8530412 G>C), RS1000046859 (3:8558745 C>T), RS1000061280 (3:8537180 C>A,T), RS1000096185 (3:8521012 C>A), RS1000132759 (3:8523878 T>G), RS1000250846 (3:8511976 G>T), RS1000305109 (3:8552735 G>A), RS1000317627 (3:8558687 G>A), RS1000320582 (3:8530809 G>A), RS1000344940 (3:8504916 G>T), RS1000419409 (3:8524636 A>G), RS1000523605 (3:8554241 A>T), RS1000535834 (3:8560524 T>C)

Disease associations

OMIM: gene MIM:604859 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST003094_1	Mitral valve prolapse	1.000000e-11
GCST003391_3	Low high density lipoprotein cholesterol levels	2.000000e-10
GCST004794_3	Brain volume in infants (intracranial brain volume)	9.000000e-07
GCST004862_41	Itch intensity from mosquito bite adjusted by bite size	8.000000e-06
GCST006616_3	Uterine fibroid number (single vs multiple)	9.000000e-07
GCST007677_1	Rumination (response to stress)	3.000000e-06
GCST009391_1203	Metabolite levels	6.000000e-06
GCST010397_14	Gut microbiota (bacterial taxa, rank normal transformation method)	1.000000e-06
GCST90002400_350	Plateletcrit	2.000000e-12
GCST90002402_297	Platelet count	7.000000e-10

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0008369	infant intracranial volume measurement
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:0009410	uterine fibroid measurement
EFO:0009857	ruminative stress response
EFO:0010418	triacylglycerol 52:6 measurement
EFO:0007874	gut microbiome measurement
EFO:0007985	platelet crit
EFO:0004309	platelet count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

67 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects expression, affects cotreatment, increases expression, decreases expression	5
Tetrachlorodibenzodioxin	affects cotreatment, increases expression	5
bisphenol A	decreases expression, increases expression	4
sodium arsenite	affects methylation, decreases expression, increases expression, increases stability	4
Cyclosporine	decreases expression, increases expression	4
Progesterone	affects cotreatment, increases expression	3
Valproic Acid	decreases methylation, increases expression	3
Resveratrol	affects cotreatment, decreases expression	2
Cadmium	increases expression	2
Silver	increases expression	2
Aflatoxin B1	increases expression, increases methylation	2
Cadmium Chloride	increases expression	2
bisphenol F	increases expression	1
2,4,6-tribromophenol	decreases expression	1
chloroacetaldehyde	decreases expression	1
cinnamaldehyde	decreases expression	1
tobacco tar	decreases expression	1
potassium chromate(VI)	decreases expression	1
triadimefon	decreases expression	1
ciglitazone	affects binding, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
monomethylarsonous acid	increases expression	1
nutlin 3	affects cotreatment, increases secretion	1
bisphenol B	increases expression	1
abrine	increases expression	1
MRK 003	decreases expression	1
bisphenol S	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1
Dasatinib	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.